Schrodinger Inc (SDGR) (Q3 2026) Earnings Call Highlights: Raised Guidance and Strong
Schrodinger Inc (SDGR) reported Q3 2026 earnings with a widened net loss of $38M, despite revenue growth. The company raised guidance, citing strong ACV and customer confidence in its technology. Revenue growth is impacted by a transition to hosted licensing. Bunsen, a new product, is in early access, and material science adoption lags behind pharma/biotech. Drug discovery revenue is milestone-dependent, with intensifying competition in AI-driven molecular discovery.
How this was made
The 30-second read
Why it matters
Guidance raise may attract new institutional interest and support the stock in the short term.
Market read
First report of raised guidance for Schrodinger; material for traders evaluating biotech AI software stocks.
What to watch
Uncertainty around Bunsen token consumption and material‑science adoption could temper upside.
Background
Schrodinger reported a widening net loss but offset by revenue growth and raised guidance for its drug discovery business.
Ticker impact
Earnings call disclosed raised three‑year drug discovery revenue guidance to $150 million and highlighted stronger demand across pharma and material‑science customers.
likely upside as investors price in higher revenue outlook
Guidance increase is a fresh, material piece of information that directly improves growth expectations.
Market effects
Positive signal for AI‑driven drug discovery and material‑science software sector.
U.S. biotech and tech investors may see a modest rally.
Limited to companies with similar AI‑driven discovery platforms.
Counterpoint
If the transition to hosted licensing continues to suppress reported revenue, the guidance lift may be insufficient.
Key entities
- CEORamy Farid
Provided commentary on technology validation and market opportunity.
- CTO/COOPat Lorton
Discussed hosted licensing transition and Bunsen platform.
